They look, move and even smell like the kind of furry Everglades marsh rabbit a Burmese python would love to eat.

In July 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) expanded its rare disease pipeline by acquiring REV102, an oral ENPP1 inhibitor for hypophosphatasia (HPP), a disorder with no existing oral ...